Diéras V et al. |
Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. |
2017 |
Lancet Oncol. |
pmid:28526536
|
Morimura O et al. |
Trastuzumab emtansine suppresses the growth of HER2-positive small-cell lung cancer in preclinical models. |
2017 |
Biochem. Biophys. Res. Commun. |
pmid:28526406
|
Menderes G et al. |
SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/Neu expression. |
2017 |
Gynecol. Oncol. |
pmid:28473206
|
Moore KN et al. |
Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α-targeting antibody-drug conjugate, in patients with solid tumors. |
2017 |
Cancer |
pmid:28440955
|
Diaby V et al. |
Economic evaluation of sequencing strategies in HER2-positive metastatic breast cancer in Mexico: a contrast between public and private payer perspectives. |
2017 |
Breast Cancer Res. Treat. |
pmid:28840424
|
Sabbaghi M et al. |
Defective Cyclin B1 Induction in Trastuzumab-emtansine (T-DM1) Acquired Resistance in HER2-positive Breast Cancer. |
2017 |
Clin. Cancer Res. |
pmid:28821558
|
van Boxtel W et al. |
Combination of docetaxel, trastuzumab and pertuzumab or treatment with trastuzumab-emtansine for metastatic salivary duct carcinoma. |
2017 |
Oral Oncol. |
pmid:28673692
|
Ait-Oudhia S et al. |
A Mechanism-Based PK/PD Model for Hematological Toxicities Induced by Antibody-Drug Conjugates. |
2017 |
AAPS J |
pmid:28646408
|
Loebrich S et al. |
Development and Characterization of a Neutralizing Anti-idiotype Antibody Against Mirvetuximab for Analysis of Clinical Samples. |
2017 |
AAPS J |
pmid:28534292
|
Meng H et al. |
A Smart Nano-Prodrug Platform with Reactive Drug Loading, Superb Stability, and Fast Responsive Drug Release for Targeted Cancer Therapy. |
2017 |
Macromol Biosci |
pmid:28464449
|